Liposomal irinotecan

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)NCT06625320RVMDPhase 3Active not recruiting2026-06Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.